University of Alberta Researchers Investigate Why Ozempic Weight Loss Varies

Scientists at the University of Alberta are investigating why weight-loss medications like Ozempic and Wegovy cause dramatic results in some patients while leaving others to face frustrating weight-loss plateaus. Researchers are examining whether metabolic adaptation—an energy-saving mode where the body burns fewer calories than expected—explains individual differences in treatment response.

Investigating Metabolic Adaptation in Semaglutide Treatment

Medications containing semaglutide belong to a class known as GLP-1 receptor agonists, which help regulate blood sugar, appetite, and body weight. SciTechDaily reported that these therapies reduce body weight by an average of 15 percent when used weekly for 68 weeks alongside lifestyle interventions. Semaglutide functions by acting on the brain to increase feelings of fullness and decrease appetite.

Despite these clinical averages, these medications do not work the same way for every patient. A multidisciplinary research team at the University of Alberta is working to improve obesity care and understand why responses vary. Investigators are exploring individual factors such as genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age, and sex.

Energy metabolism is a central focus of this ongoing research. When individuals lose weight, their bodies naturally require less energy for vital processes, physical activity, and digestion. However, some patients enter an extra energy-saving state called metabolic adaptation, or adaptive thermogenesis.

This biological mechanism causes the body to burn even fewer calories than anticipated, acting much like a light bulb that automatically dims to save electricity. SciTechDaily said that this phenomenon is a primary reason weight loss becomes harder over time and frequently results in a plateau.

Ozempic wegovy rybelsus semaglutide medications
Photo: sciencedaily.com

Weight Loss Reduces Resting Calorie Burn

Changes in body weight and composition—specifically the ratio of fat mass to fat-free mass—heavily influence energy metabolism. Both fat and fat-free tissues consume energy even during periods of rest. As patients lose these tissues, their bodies naturally burn fewer calories.

Researchers are still examining whether weight-loss medications influence these metabolic processes in unique ways. A recent review of studies investigating GLP-1 therapies and energy utilization found that existing research on resting energy use remains neutral or inconclusive, leaving the exact impact of semaglutide on energy expenditure as an open question.

To address these uncertainties, researchers at the University of Alberta utilize a whole-room indirect calorimeter. This rare research facility resembles a hotel suite and measures each component of human energy use with precision. The room isolates changes in calorie burning that occur at rest, after eating, and during physical exercise.

The research team is actively recruiting participants with blood sugar regulation issues, such as insulin resistance or Type 2 diabetes, who are about to begin semaglutide treatment. Investigators will track these participants over a six-month period to monitor changes in body weight, body composition, and energy utilization. Understanding these interactions aims to help clinicians anticipate non-responders earlier and offer alternative treatment strategies.

Evidence-Based Lifestyle Strategies for Treatment Success

Current clinical guidance indicates that patients taking semaglutide should incorporate specific lifestyle modifications to support their treatment. These recommendations include improving overall nutrition by increasing protein intake and prioritizing fresh foods such as fruits, vegetables, whole grains, lean proteins like fish and poultry, nuts, and seeds.

Patients are also advised to consume smaller portions at consistent times throughout the day, avoid skipping meals, monitor hunger and fullness cues, and choose water as their primary beverage. Health professionals recommend engaging in resistance exercise to support muscle and bone health.

The University of Alberta, founded in 1908 in Edmonton, operates as a comprehensive academic and research university across four campuses in the city. About 37,000 students from Canada and 150 other countries participate in 400 programs in 18 faculties, while the institution has produced over 260,000 graduates and counts three Nobel Prizes and 72 Rhodes Scholarships among its community’s awards.

Semaglutide treatments carry specific medical contraindications and require professional oversight.

Photo of author

Health Desk

Health Desk at Archyde.

Lakers Reclaim Western Conference Top Spot Over Spurs at 14-3

Plastic Surgeon Sentenced to Death for Murder of Attorney